Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Aducanumab (Adu), which is a human IgG1 monoclonal antibody that targets oligomer and fibril forms of beta-amyloid, has been reported to reduce amyloid pathology and improve impaired cognition after administration of a high dose (10 mg/kg) of the drug in Alzheimer’s disease (AD) clinical trials. The purpose of this study was to investigate the effects of a lower dose of Adu (3 mg/kg) with enhanced delivery via focused ultrasound (FUS) in an AD mouse model. Methods: The FUS with microbubbles opened the blood–brain barrier (BBB) of the hippocampus for the delivery of Adu. The combined therapy of FUS and Adu was performed three times in total and each treatment was performed biweekly. Y-maze test, Brdu labeling, and immunohistochemical experimental methods were employed in this study. In addition, RNA sequencing and ingenuity pathway analysis were employed to investigate gene expression profiles in the hippocampi of experimental animals. Results: The FUS-mediated BBB opening markedly increased the delivery of Adu into the brain by approximately 8.1 times in the brains. The combined treatment induced significantly less cognitive decline and decreased the level of amyloid plaques in the hippocampi of the 5×FAD mice compared with Adu or FUS alone. Combined treatment with FUS and Adu activated phagocytic microglia and increased the number of astrocytes associated with amyloid plaques in the hippocampi of 5×FAD mice. Furthermore, RNA sequencing identified that 4 enriched canonical pathways including phagosome formation, neuroinflammation signaling, CREB signaling and reelin signaling were altered in the hippocami of 5×FAD mice receiving the combined treatment. Conclusion: In conclusion, the enhanced delivery of a low dose of Adu (3 mg/kg) via FUS decreases amyloid deposits and attenuates cognitive function deficits. FUS-mediated BBB opening increases adult hippocampal neurogenesis as well as drug delivery. We present an AD treatment strategy through the synergistic effect of the combined therapy of FUS and Adu.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“The main characteristics of 5×FAD mice are extracellular amyloid deposition and gliosis beginning around 2 months [21].”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 5×
“Recently, the FDA approved Adu for the treatment of AD based on an evaluation of effects of the drug in clinical stages [5, 40].”
BackgroundResultInfluentialThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Moreno-Jiménez, E. P., Flor-García, M., Terreros-Roncal, J., Rábano, A., Cafini, F., Pallas-Bazarra, N., Ávila, J., & Llorens-Martín, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0375-9 · Cited by 1,577
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 1×
“Recently, the FDA approved Adu for the treatment of AD based on an evaluation of effects of the drug in clinical stages [5, 40].”
BackgroundHynynen, K., McDannold, N., Sheikov, N. A., Jolesz, F. A., & Vykhodtseva, N. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.046 · Cited by 679
Taupin, P. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.002 · Cited by 645
Hopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622
Rossi, C., Angelucci, A., Costantin, L., Braschi, C., Mazzantini, M., Babbini, F., Fabbri, M. E., Tessarollo, L., Maffei, L., Berardi, N., et al. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05059.x · Cited by 619
Cited by
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
Rezai, A. R., D’Haese, P.-F., Finomore, V., Carpenter, J., Ranjan, M., Wilhelmsen, K., Mehta, R. I., Wang, P., Najib, U., Vieira Ligo Teixeira, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308719 · Cited by 312
Patwardhan, A., Wilkinson, T., Meng, Y., Alhashyan, I., Black, S. E., Lipsman, N., & Masellis, M. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.85 · Cited by 15
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
Metadata
- Authors
- Kong, C., Yang, E.-J., Shin, J., Park, J., Kim, S.-H., Park, S.-W., Chang, W. S., Lee, C.-H., Kim, H., Kim, H.-S., & Chang, J. W.
- Venue
- Translational Neurodegeneration
- Published
- 2022-12-27
- Volume
- 11
- Issue
- 1
- Pages
- 57-57
- ISSN
- 2047-9158 (ISSN-L)
- OpenAlex
- W4312204280
- Cited by
- 47
- References
- 34
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model. https://app.cochat.ai/papers/10.1186/s40035-022-00333-x
- The paper
- Kong, C., Yang, E.-J., Shin, J., Park, J., Kim, S.-H., Park, S.-W., Chang, W. S., Lee, C.-H., Kim, H., Kim, H.-S., & Chang, J. W. (2022). Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model. Translational Neurodegeneration. https://doi.org/10.1186/s40035-022-00333-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.